ALTESA — Vapendavir for COPD with Rhinovirus
Sponsored by Altesa BioSciences, Inc.
Concept
To determine the optimal dose of Vapendavir to reduce the severity and duration of respiratory symptoms caused by rhinovirus infection in participants with COPD.
Key Eligibility Criteria
Below are the main inclusion and exclusion criteria for this study. The full eligibility assessment will be discussed with you by our research team during screening.
Key Inclusion Criteria
- Age 40–85 years
- Documented COPD diagnosis with post-bronchodilator FEV1/FVC <0.70
- FEV1 ≥20% and <80% predicted
- At least one COPD exacerbation within the past year
- CAT score ≥10
- Stable COPD maintenance therapy for ≥2 months
- Confirmed rhinovirus infection at randomization
Key Exclusion Criteria
- Clinically significant pulmonary diseases other than COPD
- Uncontrolled cardiovascular, hepatic, renal, neurological, or systemic disease
- Pregnant or breastfeeding
- Active hepatitis B infection
- Chronic systemic steroid use >10 mg/day
- Need for antibiotics or systemic steroids at randomization
- Participants who have taken VPV in another clinical trial
Apply for this study
Fill out the form below to see if you qualify. Our research coordinators will contact you directly to discuss your eligibility — there's no obligation to participate.
Your information is kept confidential and only used for study eligibility purposes.
Advancing research, one participant at a time.
Clinical trials depend on volunteers like you. By participating, you gain access to potential new treatments while helping researchers discover safer, more effective therapies for everyone.
- Access to investigational treatments and expert medical care
- Close monitoring by our experienced research team
- Contribute to better treatments for future patients
- Confidential — your information is protected at every step